StocksFundsScreenerSectorsWatchlists
CRL

CRL - Charles River Laboratories International Stock Price, Fair Value and News

226.63USD-0.92 (-0.40%)Market Closed

Market Summary

CRL
USD226.63-0.92
Market Closed
-0.40%

CRL Alerts

  • 1 major insider sales recently.

CRL Stock Price

View Fullscreen

CRL RSI Chart

CRL Valuation

Market Cap

11.6B

Price/Earnings (Trailing)

24.52

Price/Sales (Trailing)

2.82

EV/EBITDA

13.91

Price/Free Cashflow

17.02

CRL Price/Sales (Trailing)

CRL Profitability

EBT Margin

15.09%

Return on Equity

13.2%

Return on Assets

5.79%

Free Cashflow Yield

5.88%

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

-7.85%

Rev. Growth (Qtr)

-1.28%

CRL Earnings

Earnings (TTM)

474.6M

Earnings Growth (Yr)

-0.17%

Earnings Growth (Qtr)

114.08%

Breaking Down CRL Revenue

Last 7 days

-6.1%

Last 30 days

-15.5%

Last 90 days

6.9%

Trailing 12 Months

14.5%

How does CRL drawdown profile look like?

CRL Financial Health

Current Ratio

1.52

Debt/Equity

0.74

Debt/Cashflow

0.26

CRL Investor Care

Shares Dilution (1Y)

0.71%

Diluted EPS (TTM)

9.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.1B4.2B4.2B4.1B
20223.6B3.7B3.8B4.0B
20213.0B3.3B3.4B3.5B
20202.7B2.7B2.8B2.9B
20192.4B2.4B2.5B2.6B
20181.9B2.0B2.1B2.3B
20171.8B1.8B1.8B1.9B
20161.4B1.5B1.6B1.7B
20151.3B1.3B1.3B1.4B
20141.2B1.2B1.3B1.3B
20131.1B1.1B1.2B1.2B
20121.1B1.1B1.1B1.1B
20111.1B1.1B1.1B1.1B
20101.2B1.1B1.1B1.1B
200901.3B1.2B1.2B
20080001.3B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Charles River Laboratories International

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 08, 2024
knell michael gunnar
sold
-216,156
267
-808
csvp&chief accounting officer
Mar 04, 2024
knell michael gunnar
sold
-717,890
261
-2,750
csvp&chief accounting officer
Mar 01, 2024
parisotto shannon m
gifted
-
-
-412
cevp, disc & safety assessment
Feb 29, 2024
parisotto shannon m
sold
-959,545
253
-3,786
cevp, disc & safety assessment
Feb 29, 2024
creamer victoria l
sold
-1,268,500
253
-5,000
evp & chief people officer
Feb 22, 2024
barbo william d
sold
-1,006,420
248
-4,050
corporate executive vp & cco
Feb 16, 2024
foster james c
gifted
-
-
-4,000
chairman, president and ceo
Feb 15, 2024
girshick birgit
gifted
-
-
-424
corporate executive vp & coo
Feb 15, 2024
parisotto shannon m
sold
-1,418,770
241
-5,882
cevp, disc & safety assessment
Feb 15, 2024
laplume joseph w
sold
-200,223
238
-838
evp, corp strategy & develop

1–10 of 50

Which funds bought or sold CRL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
LVW Advisors, LLC
reduced
-2.11
83,564
768,415
0.13%
Apr 18, 2024
Capital Advisors, Ltd. LLC
added
200
1,000
1,000
-%
Apr 18, 2024
Congress Wealth Management LLC / DE /
added
0.93
1,994,880
14,717,400
0.25%
Apr 18, 2024
SJS Investment Consulting Inc.
added
166
1,458
2,168
-%
Apr 18, 2024
WOODMONT INVESTMENT COUNSEL LLC
new
-
218,115
218,115
0.02%
Apr 18, 2024
STATE OF MICHIGAN RETIREMENT SYSTEM
unchanged
-
484,737
3,801,430
0.02%
Apr 18, 2024
Piscataqua Savings Bank
unchanged
-
1,899
14,901
0.01%
Apr 18, 2024
FARMERS & MERCHANTS INVESTMENTS INC
unchanged
-
1,071
8,399
-%
Apr 18, 2024
MV CAPITAL MANAGEMENT, INC.
added
4.35
1,065
6,503
-%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
reduced
-3.99
27,664,900
303,143,000
0.47%

1–10 of 50

Are Funds Buying or Selling CRL?

Are funds buying CRL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRL
No. of Funds

Unveiling Charles River Laboratories International's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.66%
5,980,236
SC 13G/A
Jan 24, 2024
blackrock inc.
10.1%
5,195,086
SC 13G/A
Jul 07, 2023
blackrock inc.
10.2%
5,218,752
SC 13G/A
Feb 09, 2023
vanguard group inc
11.71%
5,956,960
SC 13G/A
Jan 31, 2023
fmr llc
-
0
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
4,981,145
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 09, 2022
vanguard group inc
11.63%
5,869,125
SC 13G/A
Jan 28, 2022
blackrock inc.
10.1%
5,080,026
SC 13G/A
Feb 10, 2021
vanguard group inc
10.11%
5,027,904
SC 13G/A

Recent SEC filings of Charles River Laboratories International

View All Filings
Date Filed Form Type Document
Mar 29, 2024
ARS
ARS
Mar 29, 2024
DEF 14A
DEF 14A
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 25, 2024
4/A
Insider Trading
Mar 11, 2024
4
Insider Trading

Peers (Alternatives to Charles River Laboratories International)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
174.2B
23.9B
-6.45% -5.19%
36.72
7.29
-10.33% -33.23%
39.6B
3.7B
-10.02% -2.89%
46.84
10.81
8.72% 24.44%
38.9B
6.7B
-9.88% -2.07%
31.47
5.78
-2.81% -6.58%
14.2B
9.3B
0.58% -10.70%
16.65
1.54
-6.38% -9.73%
11.6B
4.1B
-15.49% 14.49%
24.52
2.82
3.86% -2.39%
11.4B
1.9B
-6.78% 97.59%
40.46
6.07
29.17% 15.26%
11.1B
2.5B
-2.68% -8.07%
-54.22
4.43
19.93% 67.26%
10.3B
1.1B
-8.21% 57.21%
-23.68
9.51
31.99% 20.63%
MID-CAP
2.5B
929.2M
-25.64% -30.20%
1.6K
2.7
28.93% 111.61%
2.0B
563.9M
-10.26% -34.59%
-4.08
3.47
25.45% 26.76%
SMALL-CAP
430.8M
280.3M
-16.97% -3.59%
-2.26
1.54
-12.89% -148.37%
88.7M
31.2M
5.04% -86.38%
-1
2.84
5.03% -1.81%
43.1M
9.2M
0.29% -35.85%
-2.58
4.71
11.85% 44.12%
5.8M
9.0M
-32.00% -67.31%
-0.8
0.64
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Charles River Laboratories International News

Latest updates
MarketBeat18 Apr 202408:17 am
Yahoo Finance16 Apr 202403:50 pm
Yahoo Finance14 Mar 202407:00 am

Charles River Laboratories International Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-1.3%1,0131,0271,0601,0291,100989973914905896915825791743683707691668658605602
  S&GA Expenses11.9%197176200175200184132150144149172156143128128130130130136123107
EBITDA Margin2.3%0.26*0.25*0.25*0.25*0.25*0.21*0.22*0.22*0.23*0.23*0.24*0.26*---------
Interest Expenses-0.6%34.0034.0035.0034.0035.0011.004.009.0012.0016.0016.0030.0033.0019.0019.0015.0024.006.0021.0010.0017.00
Income Taxes-20.5%20.0025.0029.0027.0056.0025.0033.0016.0024.0018.0038.002.0028.0033.0016.005.0025.00-0.3215.0011.0015.00
Earnings Before Taxes-----------------10673.0059.0066.0075.00
EBT Margin2.1%0.15*0.15*0.15*0.15*0.16*0.13*0.13*0.13*0.14*0.13*0.14*0.15*---------
Net Income114.1%18787.0097.0010318796.0010993.0013810388.0062.0014310367.0051.0080.0073.0044.0055.0060.00
Net Income Margin2.0%0.11*0.11*0.12*0.12*0.12*0.12*0.12*0.12*0.11*0.12*0.12*0.12*---------
Free Cashflow7.5%221205148109235133149103229175187170---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets7.7%8,1957,6077,7727,6997,6037,3837,5297,0757,0247,0586,7205,8095,4915,2135,2415,2024,6934,5834,6253,9273,856
  Current Assets11.4%1,6091,4441,5051,4481,4391,4151,3931,3331,2741,3791,2681,4231,2011,1401,2351,2081,0219721,010866898
    Cash Equivalents76.1%277157200202234196207242246213223465233243402372240165201126197
  Inventory29.8%380293285263256262257221199182194194186181168163161156135130128
  Net PPE-------------1,124--1,0331,0441,0081,006907909
  Goodwill7.3%3,0952,8852,9172,9022,8502,7762,8602162,7122,73624061272.001,7781,7361,7322101,5221,527--
Liabilities6.6%4,5364,2564,4724,5434,5794,7114,8364,4044,4324,5944,3663,5933,3473,2883,4603,5223,0263,0183,1472,5052,518
  Current Liabilities6.2%1,0559941,0089811,0921,0141,0489941,033984930803840787728691710682636530558
  Long Term Debt5.3%2,6472,5142,6782,7442,7082,9372,9972,6762,6642,8932,7272,2021,9301,9682,2072,3271,8501,8832,0401,5411,610
Shareholder's Equity8.8%3,5973,3063,2583,1142,9762,6332,6532,6152,5392,4322,3232,1882,1181,9011,7571,6561,6381,5361,4581,4011,320
  Retained Earnings9.7%1,8871,7201,6331,5361,4331,2801,1831,07498187977568762550139933128021414197.0042.00
  Additional Paid-In Capital1.5%1,9061,8771,8501,8301,8051,7811,7611,7451,7181,7201,6911,6601,6281,6141,5901,5631,5321,5151,4981,4811,448
Shares Outstanding0.1%51.0051.0051.0051.0051.0051.0051.0051.0050.0050.0050.0050.00---------
Minority Interest13.1%5.005.006.005.005.006.005.005.004.005.005.004.004.005.004.004.003.004.003.003.002.00
Float---10,687---11,392---18,339---8,333---6,797--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations7.5%220,943205,450148,122109,383234,757132,779149,474102,630229,258174,722186,590170,229138,379177,300162,30668,590180,677155,847129,55314,859139,973
  Share Based Compensation-14.4%19,52122,79716,27013,46022,06921,99914,93014,61919,18522,02317,07713,18915,36816,87013,14310,96013,84214,02516,50512,89911,438
Cashflow From Investing-199.6%-238,371-79,557-76,609-168,61844,383-92,186-462,114-98,0059,307-355,050-954,193-137,996-88,423-70,810-28,626-413,685-70,871-61,393-528,425-20,813-70,956
Cashflow From Financing175.9%123,568-162,866-71,46425,241-248,956-51,594271,436-13,283-218,972178,895517,955194,720-59,229-268,639-104,096479,212-39,044-133,443473,507-69,083563
  Buy Backs265.8%13938.004,96619,01215924.004,47433,9942671434,26936,02874.0011211823,67547.0015712317,76055.00

CRL Income Statement

2023-12-30
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Dec. 25, 2021
Total revenue$ 4,129,409$ 3,976,060$ 3,540,160
Costs and expenses:   
Selling, general and administrative747,855665,098619,919
Amortization of intangible assets137,440146,578124,857
Operating income617,261650,975589,862
Other income (expense):   
Interest income5,196780652
Interest expense(136,710)(59,291)(73,910)
Other income (expense), net95,53730,523(35,894)
Income before income taxes581,284622,987480,710
Provision for income taxes100,914130,37981,873
Net income480,370492,608398,837
Less: Net income attributable to noncontrolling interests5,7466,3827,855
Net income attributable to common shareholders$ 474,624$ 486,226$ 390,982
Earnings per common share   
Basic (in dollars per share)$ 9.27$ 9.57$ 7.77
Diluted (in dollars per share)$ 9.22$ 9.48$ 7.60
Weighted-average number of common shares outstanding:   
Basic (in shares)51,22750,81250,293
Diluted (in shares)51,45151,30151,425
Cost of services provided (excluding amortization of intangible assets)   
Total revenue$ 3,440,019$ 3,216,904$ 2,755,579
Costs and expenses:   
Cost of services provided and products sold2,295,9832,143,3181,837,487
Cost of products sold (excluding amortization of intangible assets)   
Total revenue689,390759,156784,581
Costs and expenses:   
Cost of services provided and products sold$ 330,870$ 370,091$ 368,035

CRL Balance Sheet

2023-12-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 276,771$ 233,912
Trade receivables and contract assets, net of allowances for credit losses of $25,722 and $11,278, respectively780,375752,390
Inventories380,259255,809
Prepaid assets87,87989,341
Other current assets83,378107,580
Total current assets1,608,6621,439,032
Property, plant and equipment, net1,639,7411,465,655
Venture capital and strategic equity investments243,811311,602
Operating lease right-of-use assets, net394,029391,762
Goodwill3,095,0452,849,903
Intangible assets, net864,051955,275
Deferred tax assets40,27941,262
Other assets309,383148,279
Total assets8,195,0017,602,770
Current liabilities:  
Accounts payable168,937205,915
Accrued compensation213,290197,078
Deferred revenue241,820264,259
Accrued liabilities227,825219,758
Other current liabilities203,210204,575
Total current liabilities1,055,0821,091,585
Long-term debt, net and finance leases2,647,1472,707,531
Operating lease right-of-use liabilities419,234389,745
Deferred tax liabilities191,349215,582
Other long-term liabilities223,191174,822
Total liabilities4,536,0034,579,265
Commitments and contingencies (Notes 2, 11, 13, 14 and 18)
Redeemable noncontrolling interest56,72242,427
Equity:  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock, $0.01 par value; 120,000 shares authorized; 51,338 shares issued and outstanding as of December 30, 2023 and 50,944 shares issued and outstanding as of December 31, 2022513509
Additional paid-in capital1,905,5781,804,940
Retained earnings1,887,2181,432,901
Treasury stock, at cost, zero shares as of December 30, 2023 and December 31, 202200
Accumulated other comprehensive loss(196,427)(262,057)
Total equity attributable to common shareholders3,596,8822,976,293
Noncontrolling interests (nonredeemable)5,3944,785
Total equity3,602,2762,981,078
Total liabilities, redeemable noncontrolling interests and equity$ 8,195,001$ 7,602,770
CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
 CEO
 WEBSITEcriver.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES20000

Charles River Laboratories International Frequently Asked Questions


What is the ticker symbol for Charles River Laboratories International? What does CRL stand for in stocks?

CRL is the stock ticker symbol of Charles River Laboratories International. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Charles River Laboratories International (CRL)?

As of Fri Apr 19 2024, market cap of Charles River Laboratories International is 11.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers. The fair value of Charles River Laboratories International is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Charles River Laboratories International is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Charles River Laboratories International a good stock to buy?

The fair value guage provides a quick view whether CRL is over valued or under valued. Whether Charles River Laboratories International is cheap or expensive depends on the assumptions which impact Charles River Laboratories International's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRL.

What is Charles River Laboratories International's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CRL's PE ratio (Price to Earnings) is 24.52 and Price to Sales (PS) ratio is 2.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Charles River Laboratories International's stock?

In the past 10 years, Charles River Laboratories International has provided 0.146 (multiply by 100 for percentage) rate of return.